Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | Brazil/Mexico | 2015
How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…
The Impact of Biosimilars in NHL, Breast Cancer, and Colorectal Cancer | Physician & Payer Forum | Brazil and Mexico | 2015
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
Biosimilars Advisory Service : Global Biosimilars Markets – Regulations, Pipelines, and Major Players | G7 | 2015
Latest update: Global Biosimilars Pipeline updated on 31 July 2015 The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75%…
EU5 Market Access Opportunities and Challenges for Current and Emerging Rheumatoid Arthritis Agents Amid the Launches of Oral Jak Inhibitors and Biosimilars | Physician & Payer Forum | EU5 | 2014
Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that typically results in permanent, debilitating tissue damage. Biological…
Psoriasis (How Will the Launches of Efficacious Biologics and Novel Oral Agents Affect Psoriasis Treatment and Reimbursement? Insights from U.S. Physicians and Payers) | US | 2014
Psoriasis is a chronic inflammatory skin disorder that is managed with systemic therapies for moderate to severe patients who fail first-line topical therapies and/or phototherapy. Dermatologists…
Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology (Physician Perspectives) | Biosimilars Advisory Service | US/Eu5/Japan | 2014
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
Erythropoiesis-Stimulating Agents, Insulin, and Human Growth Hormone (Physician Perspectives) | Biosimilars Advisory Service | US/EU5/Japan | 2014
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…
Shifts in the U.S. Rheumatoid Arthritis Market Access Landscape Due to Oral Kinase Inhibitors, New Biologics, and Biosimilars: Insights from Payers and Physicians | Physician & Payer Forum | US | 2014
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar…
Biosimilars Advisory Service: Physician Perspectives on Biologics in Immunology and Infectious Disease
With biosimilar infliximab approved in Europe and filed for approval in the United States, rheumatologists and gastroenterologists will soon have the opportunity to prescribe biosimilars to their…
